Search results for " Cholesterol"

showing 10 items of 243 documents

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

2017

Abstract Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major…

0301 basic medicineApolipoprotein ECandidate geneSettore MED/09 - Medicina InternaDatabases FactualApolipoprotein BDNA Mutational AnalysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityPCSK90302 clinical medicineRisk FactorsReceptorsGeneticsHomozygoteAutosomal dominant traitPathogenic variantsGeneral MedicinePrognosisAPOB; Familial hypercholesterolemia; LDLR; PCSK9; Pathogenic variantsCholesterolPhenotypeItalyAutosomal Recessive HypercholesterolemiaApolipoprotein B-100lipids (amino acids peptides and proteins)Proprotein Convertase 9APOBCardiology and Cardiovascular MedicinePreliminary DataGenetic MarkersFamilial hypercholesterolemiaLDLRPCSK9APOBPathogenic variantsHeterozygoteFamilial hypercholesterolemiaBiologyPathogenic variantLDLHyperlipoproteinemia Type II03 medical and health sciencesDatabasesmedicineInternal MedicineHumansAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Internal Medicine; Cardiology and Cardiovascular MedicineGenetic Predisposition to DiseaseFactualPCSK9Settore MED/13 - ENDOCRINOLOGIAAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Cardiology and Cardiovascular Medicine; Internal Medicinemedicine.diseaseAtherosclerosis030104 developmental biologyLDLRReceptors LDLMutationbiology.proteinAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Apolipoprotein B-100; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Preliminary Data; Prognosis; Proprotein Convertase 9; Receptors LDL; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine
researchProduct

CD36 gene polymorphism is associated with Alzheimer's disease.

2017

IF 3.112; International audience; CD36 gene encodes a membrane glycoprotein (type B scavenger receptor) present on the surface of many types of cells and having multiple cellular functions ranging from angiogenesis to gustatory perception of fatty acids. Using a case control genetic association approach we have analyzed selected single nucleotide polymorphisms (SNP's) in a total of 859 patients with Alzheimer's disease (AD) and controls and have identified the allele A in rs3211892 polymorphism of CD36 gene as significantly increasing the risk of AD. Additionally we have investigated, in the same sample of control subjects and patients, SNP's in ApoE gene and confirmed that the previously i…

0301 basic medicineApolipoprotein EMESH : Oxidative StressCD36 AntigensMaleMESH : Polymorphism GeneticCD36MESH : AgedMESH : Alzheimer DiseaseMESH : GenotypeBiochemistryGeneMESH: Genotype0302 clinical medicineMESH: CholesterolMESH : FemaleMESH : CholesterolGeneticsMESH: AgedMESH: Oxidative StressbiologyMESH: Polymorphism Single NucleotideMESH : Polymorphism Single NucleotideMESH: Genetic Predisposition to DiseaseGeneral Medicine3. Good healthMESH : Antigens CD36CholesterolInterleukin 18FemaleApoEGenotypeMESH : MaleSingle-nucleotide polymorphismPolymorphism Single NucleotideMMSEAssociation03 medical and health sciencesAlzheimer DiseaseMESH: Polymorphism GeneticSNPHumansGenetic Predisposition to Disease[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyAllelePolymorphism[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyGenetic associationAgedPolymorphism GeneticMESH: HumansMESH: Antigens CD36MESH : HumansMESH: MaleOxidative Stress030104 developmental biologybiology.proteinMESH : Genetic Predisposition to DiseaseGene polymorphismCD36MESH: Female030217 neurology & neurosurgeryMESH: Alzheimer Disease
researchProduct

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)

2017

Background and aims: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). Methods: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationw…

0301 basic medicineCandidate geneGenetic testingSettore MED/09 - Medicina InternaDatabases FactualDNA Mutational AnalysisDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematology0302 clinical medicineDyslipidemias; Genetic testing; National network; Internal Medicine; Cardiology and Cardiovascular MedicineRisk FactorsProspective StudiesProgram DevelopmentProspective cohort studymedicine.diagnostic_testGeneral MedicinePrognosisCholesterolPhenotypeItalyCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyNational networkDyslipidemias; Genetic testing; National networkMEDLINEHyperlipoproteinemia Type II03 medical and health sciencesDatabasesInternal medicinemedicineInternal MedicineHumansGenetic Predisposition to DiseaseFactualGenetic testingRetrospective StudiesDyslipidemiasbusiness.industrySettore MED/13 - ENDOCRINOLOGIARetrospective cohort studymedicine.diseaseAtherosclerosisDyslipidemias; Genetic testing; National network; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Prognosis; Program Development; Prospective Studies; Retrospective Studies; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine030104 developmental biologyEndocrinologyDyslipidemiaGenetic markerMutationbusiness
researchProduct

Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia

2017

Several risk factors such as abnormality of lipid metabolism (e.g. high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C)) play a central role in the aetiology of cardiovascular disease (CVD). Nutraceutical combination together with a cholesterol- lowering action, when associated with suitable lifestyle, should furnish an alternative to pharmacotherapy in patients reporting statin-intolerance and in subjects at low cardiovascular risk. The present review is focused on nutraceuticals and their synergetic combinations demonstrating a beneficial effect in the management of dyslipidaemia. Several nutraceu…

0301 basic medicineDyslipidaemiaCombination therapyLow density lipoprotein cholesterol030204 cardiovascular system & hematologyReductaseBiologyPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalBerberineDrug DiscoverymedicineRed yeast riceHumansEndothelial dysfunctionEndothelial dysfunctionDyslipidemiasCarotidDietary SupplementPharmacologyCholesterolLipid metabolismLipidCardiovascular riskmedicine.diseaseLipidsIntima media thickne030104 developmental biologyDyslipidemiachemistryDietary SupplementsDrug Therapy Combinationlipids (amino acids peptides and proteins)NutraceuticalHumanCurrent Pharmaceutical Design
researchProduct

First international descriptive and interventional survey for cholesterol and non-cholesterol sterol determination by gas- and liquid-chromatography–…

2019

International audience; Serum concentrations of lathosterol, the plant sterols campesterol and sitosterol and the cholesterol metabolite 5alpha-cholestanol are widely used as surrogate markers of cholesterol synthesis and absorption, respectively. Increasing numbers of laboratories utilize a broad spectrum of well-established and recently developed methods for the determination of cholesterol and non-cholesterol sterols (NCS). In order to evaluate the quality of these measurements and to identify possible sources of analytical errors our group initiated the first international survey for cholesterol and NCS. The cholesterol and NCS survey was structured as a two-part survey which took place…

0301 basic medicineEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryCholesterol balancechemistry.chemical_compound0302 clinical medicineEndocrinologySurveys and QuestionnairesPhytosterolABSORPTIONMedicineCholesterol absorptionPRECURSORSNormal laboratoryPhytosterols[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismSERUM PLANT STEROLSSitosterol3. Good healthCholestanolCholesterolAtherosclerosi030220 oncology & carcinogenesisCholesterol synthesisMolecular Medicinelipids (amino acids peptides and proteins)HumanCholesterol synthesisChromatography GasCholesterol synthesiCampesterolatherosclerosis; cholesterol absorption; cholesterol balance; cholesterol synthesis; phytosterols; surrogate markerLathosterolDeuterium labelledArticle03 medical and health sciencesHumansMolecular BiologyChromatographybusiness.industryCholesterolCell BiologyAtherosclerosisSitosterolsSterol030104 developmental biologychemistryChromatography Ga3121 General medicine internal medicine and other clinical medicine1182 Biochemistry cell and molecular biologyGas chromatographySurrogate markerbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionChromatography Liquid
researchProduct

Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regul…

2020

Objectives: ATP-binding cassette transporter A1 (ABCA1) is a key player in the reverse cholesterol transport (RCT) and HDL biogenesis. Since RCT is compromised as a result of ABCA1 dysfunction in diabetic state, the objective of this study was to investigate the regulation of ABCA1 in a stably transfected 293 cells expressing ABCA1 under the control of cAMP response element. Methods: To delineate transcriptional and posttranscriptional regulation of ABCA1, 293 cells were stably transfected with the full length ABCA1 cDNA under the control of CMV promoter harboring cAMP response element. cAMP-mediated regulation of ABCA1 and cholesterol efflux were studied in the presence of 8-Br-cAMP and af…

0301 basic medicineEndocrinology Diabetes and MetabolismResponse elementABCA1030209 endocrinology & metabolismDiabeteProtein kinase03 medical and health sciences0302 clinical medicinecAMPpolycyclic compoundsInternal MedicineABCA1 GeneMedicinecardiovascular diseasesProtein kinase Abiologybusiness.industryReverse cholesterol transportHEK 293 cellsnutritional and metabolic diseaseshemic and immune systemsTransfectionCell biology030104 developmental biologyCell cultureABCA1biology.proteinlipids (amino acids peptides and proteins)Stably transfectedbusinessRegulationResearch ArticleJournal of Diabetes & Metabolic Disorders
researchProduct

International descriptive and interventional survey for oxycholesterol determination by gas- and liquid-chromatographic methods

2018

International audience; Increasing numbers of laboratories develop new methods based on gas-liquid and high-performance liquid chromatography to determine serum concentrations of oxygenated cholesterol metabolites such as 7alpha-, 24(S)-, and 27-hydroxycholesterol. We initiated a first international descriptive oxycholesterol (OCS) survey in 2013 and a second interventional survey 2014 in order to compare levels of OCS reported by different laboratories and to define possible sources of analytical errors. In 2013 a set of two lyophilized serum pools (A and B) was sent to nine laboratories in different countries for OCS measurement utilizing their own standard stock solutions. In 2014 eleven…

0301 basic medicineHigh performance-liquid chromatography[SDV.BIO]Life Sciences [q-bio]/BiotechnologyChromatography GasDeuterium labelledHigh-performance liquid chromatographyBiochemistryBile acid precursor03 medical and health sciencesOxysterolgasSurveys and QuestionnairesHumansSurveys and QuestionnaireliquidReference standardsbile acid precursors; gas-liquid chromatography; high performance-liquid chromatography; isotope dilution; mass spectrometry; oxysterol; cholesterol; chromatography gas; chromatography liquid; humans; reference standards; surveys and questionnaires; biochemistryChromatographyMass spectrometry[CHIM.ORGA]Chemical Sciences/Organic chemistryBile acid precursorsChromatography liquidGeneral MedicineStandard methodsSerum concentrationReference Standards16. Peace & justiceIsotope dilution3. Good health030104 developmental biologyGas-liquid chromatographyCholesterolChromatography GaEnvironmental sciencechromatographyReference StandardGas chromatographybile acid precursorsChromatography LiquidHuman
researchProduct

Pathophysiology of non alcoholic fatty liver disease

2016

The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style and inflammation, which have a major impact on the severity of the clinicopathologic outcome of non-alcoholic fatty liver disease. A short comprehensive review is provided on current knowledge of the pathophysiological interplay among major circulating effectors/mediators of fatty liver, such as circulating lipids, mediators released by adipose, muscle and liver tissues and pancreatic and gut hormones in relation to diet, exercise and inflammation.

0301 basic medicineLeptinAdipose tissueReviewDiseaseCatalysilcsh:Chemistry0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInsulinAdiponectin; Cholesterol; Fatty liver; Free fatty acids; Ghrelin; Glucagon; Glucagon-like peptide 1; Insulin; Insulin resistance; Irisin; Leptin; Selenoprotein P; Adipose Tissue; Gastrointestinal Hormones; Humans; Lipids; Muscles; Non-alcoholic Fatty Liver Disease; Pancreatic Hormones; Catalysis; Molecular Biology; Computer Science Applications1707 Computer Vision and Pattern Recognition; Spectroscopy; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic Chemistrylcsh:QH301-705.5SpectroscopyGastrointestinal HormoneFree fatty acidMusclesFatty liverComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineLipidLipidsPathophysiologyGhrelinComputer Science ApplicationsCholesterolAdipose TissueMuscleAdiponectinmedicine.symptomHumanmedicine.medical_specialtyIrisinSettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismInflammationBiologyFree fatty acidsCatalysisPancreatic HormoneGastrointestinal HormonesInorganic Chemistry03 medical and health sciencesInternal medicineFatty liverSelenoprotein PmedicineHumansPhysical and Theoretical ChemistryGlucagon-like peptide 1Molecular BiologyOrganic ChemistryNon alcoholicInsulin resistancemedicine.diseaseGut hormonesGlucagonPancreatic Hormones030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999Metabolic syndrome
researchProduct

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease

2019

AbstractNonalcoholic fatty liver disease (NAFLD) is a rising cause of hepatocellular carcinoma (HCC). We examined whether inherited pathogenic variants in candidate genes (n = 181) were enriched in patients with NAFLD-HCC. To this end, we resequenced peripheral blood DNA of 142 NAFLD-HCC, 59 NAFLD with advanced fibrosis, and 50 controls, and considered 404 healthy individuals from 1000 G. Pathogenic variants were defined according to ClinVar, likely pathogenic as rare variants predicted to alter protein activity. In NAFLD-HCC patients, we detected an enrichment in pathogenic (p = 0.024), and likely pathogenic variants (p = 1.9*10−6), particularly in APOB (p = 0.047). APOB variants were asso…

0301 basic medicineMaleCandidate geneApolipoprotein Blcsh:MedicineGastroenterologyLiver diseasechemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseSequestosome-1 ProteinGenetic riskHCClcsh:ScienceMultidisciplinarybiologyLiver NeoplasmsMiddle Aged3. Good healthCholesterolHepatocellular carcinomaApolipoprotein B-100FemaleAged; Apolipoprotein B-100; Carcinoma Hepatocellular; Case-Control Studies; Cholesterol HDL; Female; Genetic Predisposition to Disease; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Reproducibility of Results; Risk Factors; Sequestosome-1 Proteinmedicine.medical_specialtyCarcinoma HepatocellularGlial Cell Line-Derived Neurotrophic Factor ReceptorsHDLSettore BIO/18 - GENETICAdigestive systemArticle03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseGeneAgedCholesterolbusiness.industrylcsh:RCarcinomaCholesterol HDLnutritional and metabolic diseasesReproducibility of ResultsHepatocellularmedicine.diseasedigestive system diseases030104 developmental biologychemistryNASH HCCCase-Control Studiesbiology.proteinlcsh:Qgeneticbusiness030217 neurology & neurosurgery
researchProduct

Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and fam…

2017

Background The most frequent monogenic causes of low plasma cholesterol are familial hypobetalipoproteinemia (FHBL1) because of truncating mutations in apolipoprotein B coding gene (APOB) and familial combined hypolipidemia (FHBL2) due to loss-of-function mutations in ANGPTL3 gene. Objective A direct comparison of lipid phenotypes of these 2 conditions has never been carried out. In addition, although an increased prevalence of liver steatosis in FHBL1 has been consistently reported, the hepatic consequences of FHBL2 are not well established. Methods We investigated 350 subjects, 67 heterozygous carriers of APOB mutations, 63 carriers of the p.S17* mutation in ANGPTL3 (57 heterozygotes and …

0301 basic medicineMaleHepatic steatosisSettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolism030204 cardiovascular system & hematologymedicine.disease_causeANGPTL3 gene; APOB gene; Familial combined hypolipidemia; Familial hypobetalipoproteinemia; HDL cholesterol; Hepatic steatosis; Low cholesterol syndromesHypobetalipoproteinemiasExon0302 clinical medicineHDL cholesterolANGPTL3Nutrition and DieteticFamilial hypobetalipoproteinemiaGeneticsMutationNutrition and Dieteticsbiologyhepatic steatosisHomozygoteANGPTL3 geneMiddle AgedLow cholesterol syndromesPhenotypePhenotypelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineANGPTL3 gene; APOB gene; familial combined hypolipidemia; familial hypobetalipoproteinemia; HDL cholesterol; hepatic steatosis; low cholesterol syndromesmedicine.medical_specialtyHeterozygoteLow cholesterol syndromeHepatic steatosi03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansAPOB geneFamilial combined hypolipidemiaGeneAgedAngiopoietin-Like Protein 3Apolipoproteins Bbusiness.industryHeterozygote advantagemedicine.disease030104 developmental biologyEndocrinologyAngiopoietin-like ProteinsMutationbiology.proteinlow cholesterol syndromesSteatosisbusiness
researchProduct